NCT01685619View on ClinicalTrials.gov

AML-MDS Novel Prognostic Tests Clinical Study

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

October 2, 2012

Primary Completion Date

January 24, 2018

Study Completion Date

January 24, 2018

Conditions
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Trial Locations (6)

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E3

Vancouver General Hospital, Vancouver

R3M 1A5

CancerCare Manitoba, Winnipeg

B3H 2Y9

Queen Elizabeth II Health Sciences Centre, Halifax

M5G 2M9

Princess Margaret Cancer Centre (formerly Princess Margaret Hospital), Toronto

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
collaborator

Terry Fox Research Institute

OTHER

lead

Nova Scotia Health Authority

OTHER

NCT01685619 - AML-MDS Novel Prognostic Tests Clinical Study | Biotech Hunter | Biotech Hunter